MindMed, a leading biotech firm developing psychedelic-inspired therapies, and Datavant, Inc., a leader in assisting healthcare organizations in safely connecting their data, announced a collaboration in which MindMed will use Datavant's privacy-protecting technology to link MindMed's clinical trial data to external data from both clinical and real-world sources. In addition, MindMed intends to use Datavant's connecting technology across the drug lifecycle, including discovery, clinical development, and commercialization.
MindMed will create broad and comprehensive datasets via data linking to understand better the real-world treatment, service usage, and healthcare experiences of patients with psychiatric and drug use disorders. This data, as well as a better understanding of both the relevant illness and the pathways of treatment that patients take, will assist MindMed's clinical trial planning, execution, and preparation for commercialization of its novel molecules.
MindMed is a clinical-stage biotech company that discovers, develops, and sells psychedelic-inspired medicines and therapies to treat addiction and mental disease. The company is building a compelling drug development pipeline of novel treatments based on psychedelic drugs such as psilocybin, LSD, MDMA, DMT, and 18-MC, an ibogaine derivative. MindMed's executive team brings extensive biopharmaceutical expertise to the company's approach to creating the next generation of psychedelic-inspired medicines and therapies.
The goal of Datavant is to connect the world's health data to enhance patient outcomes. Datavant aims to minimize the friction associated with data sharing in the healthcare sector by developing the technology that preserves patients' privacy while allowing the linkage of de-identified patient records across datasets. Datavant is based in San Francisco.